Orphan Drug and FDA Breakthrough Therapy designations. The first and only reversal agent indicated for patients being treated with rivaroxaban (Xarelto, Janssen) and apixaban (Eliquis, Bristol-Myers Squibb/Pfizer), when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding, has been approved by the FDA.Ĭoagulation factor Xa (recombinant), inactivated-zhzo (Andexxa, Portola received both U.S.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |